Cargando…

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma

BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with poor prognosis, requiring novel anticancer strategies. METHODS: Mantle cell lymphoma cell lines with known p53 status were treated with GUT-70, a tricyclic coumarin derived from Calophyllum brasiliense, and the biological a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, L, Tabe, Y, Kimura, S, Zhou, Y, Kuroda, J, Asou, H, Inaba, T, Konopleva, M, Andreeff, M, Miida, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039813/ https://www.ncbi.nlm.nih.gov/pubmed/21139584 http://dx.doi.org/10.1038/sj.bjc.6606007

Ejemplares similares

Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation
por: Zhang, Y, et al.
Publicado: (2014)

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
por: Xu, W, et al.
Publicado: (2007)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells
por: Peduto Eberl, L, et al.
Publicado: (2003)

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
por: Wu, X, et al.
Publicado: (2009)

Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
por: Kang, B H, et al.
Publicado: (2011)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
por: Courtin, Aurelie, et al.
Publicado: (2016)

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
por: Stingl, L, et al.
Publicado: (2010)

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer
por: Lee, S J, et al.
Publicado: (2014)

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
por: Lin, W-H, et al.
Publicado: (2012)

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
por: Bocci, G, et al.
Publicado: (2005)

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells
por: Serova, M, et al.
Publicado: (2007)

Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells
por: Fabian, I, et al.
Publicado: (2006)

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
por: Benhadji, K A, et al.
Publicado: (2008)

Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo
por: Gibert, B, et al.
Publicado: (2012)

Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth
por: Wang, M-H, et al.
Publicado: (2004)

A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth
por: Li, D, et al.
Publicado: (2014)

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia
por: Gallagher, W M, et al.
Publicado: (2005)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy
por: Faisal, Amir, et al.
Publicado: (2017)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
por: Peasland, A, et al.
Publicado: (2011)

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
por: Yoshida, T, et al.
Publicado: (2014)

Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro
por: Etminan, N, et al.
Publicado: (2011)

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth
por: Patel, J B, et al.
Publicado: (2007)

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
por: Dredge, K, et al.
Publicado: (2011)

Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
por: Qu, Sifeng, et al.
Publicado: (2018)

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
por: Gritzapis, A D, et al.
Publicado: (2005)

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies
por: Arts, J, et al.
Publicado: (2007)

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
por: Stish, B J, et al.
Publicado: (2009)

Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1
por: Sekihara, Kazumasa, et al.
Publicado: (2017)

Combination therapy with PEG-IFN-α and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53
por: Hagiwara, S, et al.
Publicado: (2007)

Correction: Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1
por: Sekihara, Kazumasa, et al.
Publicado: (2019)

The neuro-steroid, 3β androstene 17α diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathways
por: Graf, M R, et al.
Publicado: (2007)

C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer
por: Yamaguchi, K, et al.
Publicado: (2010)

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
por: Yokoyama, H, et al.
Publicado: (2006)

Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells
por: Jeon, T-Y, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7f7qbtirmjmq1idkjfssnfqr11